Other Financings Of Public Biotechnology Companies: April 2001

Total: $95.16M

Company (Symbol)#

Type Of Financing

Number Of Shares, Units Or Warrants (M)

Amount Raised (M)

Investors; Placement Agents; Details (Date)@

Bioniche Life Sciences Inc. (Canada; TSE:BNC)

Financing from the Canadian government

N/A

C$17.2 (US$10.99)

Bioniche entered into an agreement with the Canadian government for US$10.99M in funding for research and development (4/9)

Cel-Sci Corp. (AMEX:CVM)

Equity financing agreement

N/A

­

Cel-Sci entered a $10M equity financing agreement with an undisclosed private investor, giving the company the right to periodically draw down funds for the next two years; shares will be sold to the private investor at an 11% discount to market price (4/12)

Cytomedix Inc. (OTC BB:CYDX)

Equity financing-agreement< /TD>

N/A

­

Cytomedix entered a stock purchase agreement with Fusion Capital Fund II LLC, allowing Fusion to buy up to $14.7M; the funding will occur periodically (4/23)

DepoMed Inc. (AMEX:DMI)

Draw-down financing

N/A

­

GATX Ventures Inc. agreed to provide up to $2M in financing for DepoMed, which expects to draw down the financing over the next nine months (4/11)

Gliatech Inc. (GLIA)

Financing deal

N/A

$5

Gliatech entered a financing deal with Paul Capital Royalty Acquisition Fund LP receiving a $5M cash infusion up front, and an additional $10M upon the commercial relaunch of Adcon-L in the U.S. and Europe; Gliatech has the option to draw down another $15M later; in return, Paul Capital gains a 2.5% royalty on net sales of Adcon products through 2012, or a guaranteed minimum annual royalty rate of $1.6M (4/26)

International Wex Technologies Inc. (Canada; CDNX:WXI)

Private placement of common stock

0.3S

$0.64

International Wex expects to raise about $640,000 through the private placement of 300,000 shares at $2.12 per share, with two-year warrants attached for 300,000 shares exercisable at $2.49 each the first year and $2.99 each the second year (4/23)

Oxford Biomedica plc (UK; LSE:OXB)

Private placement of common stock

59.2S

US$7

Oxford raised about US$7M more in a private placement begun in March; at that time, it expected to raise US$39.53M (see April 9, 2001, issue of Financial Watch) (4/17)

Transgene SA (France; TRGNY)

Rights offering to existing shareholders

5.31S

EUR79.72 (US$71.53)

Transgene will offer the shares at EUR15 per share to existing shareholders and holders of its American depository shares in the ratio of 11 share rights to purchase 10 new shares or 33 ADS rights to purchase 30 new ADSs (4/23)

Notes:

# Unless otherwise indicated, shares are traded on the Nasdaq exchange.

@ Dates refer to the date of the press release.

N/A = Not available or reported.

AMEX = American Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; OTC BB = Over the Counter Bulletin Board; TSE = Toronto Stock Exchange

No Comments